NASDAQ:ALKS Alkermes Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alkermes Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.03 -0.42 (-2.28 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$17.45Now: $18.03▼$19.0450-Day Range$16.16MA: $17.56▼$18.7852-Week Range$11.98Now: $18.03▼$21.93Volume4.05 million shsAverage Volume1.65 million shsMarket Capitalization$2.87 billionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.80, Alkermes has a forecasted upside of 9.8% from its current price of $18.03.Amount of Analyst CoverageAlkermes has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesAlkermes has received 635 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlkermes has received 477 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlkermes has received 57.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote “Outperform” if you believe ALKS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.49% of the stock of Alkermes is held by insiders.Percentage Held by Institutions98.93% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to grow in the coming year, from ($0.47) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is -22.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is -22.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALKS Previous Symbol CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone353-1772-8000Debt Debt-to-Equity Ratio0.26 Current Ratio2.95 Quick Ratio2.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.17 billion Price / Sales2.45 Cash Flow$0.59 per share Price / Cash Flow30.61 Book Value$6.89 per share Price / Book2.62Profitability EPS (Most Recent Fiscal Year)$0.07 Net Income$-196,620,000.00 Net Margins-10.87% Return on Equity4.47% Return on Assets2.66%Miscellaneous Employees2,235 Outstanding Shares159,044,000Market Cap$2.87 billion Next Earnings Date10/28/2020 (Estimated) OptionableOptionable $18.03 -0.42 (-2.28 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ALKS News and Ratings via Email Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Alkermes (NASDAQ:ALKS) Frequently Asked Questions How has Alkermes' stock price been impacted by COVID-19 (Coronavirus)? Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALKS stock has increased by 11.0% and is now trading at $18.03. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Alkermes? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes. When is Alkermes' next earnings date? Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020. View our earnings forecast for Alkermes. How were Alkermes' earnings last quarter? Alkermes Plc (NASDAQ:ALKS) released its quarterly earnings results on Wednesday, July, 29th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.19. The company earned $247.53 million during the quarter, compared to the consensus estimate of $232.70 million. Alkermes had a positive return on equity of 4.47% and a negative net margin of 10.87%. Alkermes's quarterly revenue was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 EPS. View Alkermes' earnings history. What guidance has Alkermes issued on next quarter's earnings? Alkermes issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of $0.00-0.19 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.11. The company issued revenue guidance of $965-1.005 billion, compared to the consensus revenue estimate of $983.05 million. What price target have analysts set for ALKS? 10 brokers have issued twelve-month price targets for Alkermes' shares. Their forecasts range from $15.00 to $28.00. On average, they expect Alkermes' stock price to reach $19.80 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View analysts' price targets for Alkermes. Who are some of Alkermes' key competitors? Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Pfizer (PFE), Celgene (CELG), Starbucks (SBUX), Johnson & Johnson (JNJ), Tesla (TSLA) and Alibaba Group (BABA). Who are Alkermes' key executives? Alkermes' management team includes the following people: Mr. Richard F. Pops, Chairman & CEO (Age 57)Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)Mr. James M. Frates, Sr. VP & CFO (Age 52)Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51) What is Alkermes' stock symbol? Alkermes trades on the NASDAQ under the ticker symbol "ALKS." Who are Alkermes' major shareholders? Alkermes' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.69%), First Trust Advisors LP (2.52%), Point72 Asset Management L.P. (2.03%), UBS Group AG (1.24%), Goldman Sachs Group Inc. (1.11%) and Krensavage Asset Management LLC (0.98%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View institutional ownership trends for Alkermes. Which major investors are selling Alkermes stock? ALKS stock was sold by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, AQR Capital Management LLC, Cubist Systematic Strategies LLC, PDT Partners LLC, Meditor Group Ltd, Two Sigma Advisers LP, Bank of America Corp DE, and Federated Hermes Inc.. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops. View insider buying and selling activity for Alkermes. Which major investors are buying Alkermes stock? ALKS stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., UBS Group AG, First Trust Advisors LP, Krensavage Asset Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Goldman Sachs Group Inc., WINTON GROUP Ltd, and Jacobs Levy Equity Management Inc.. View insider buying and selling activity for Alkermes. How do I buy shares of Alkermes? Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alkermes' stock price today? One share of ALKS stock can currently be purchased for approximately $18.03. How big of a company is Alkermes? Alkermes has a market capitalization of $2.87 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe. What is Alkermes' official website? The official website for Alkermes is www.alkermes.com. How can I contact Alkermes? Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
